| editorial | Q871232 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1004278328 |
| P356 | DOI | 10.1208/S12248-010-9188-Y |
| P932 | PMC publication ID | 2895450 |
| P698 | PubMed publication ID | 20383669 |
| P5875 | ResearchGate publication ID | 43100622 |
| P2093 | author name string | Malcolm Rowland | |
| Gary T Emmons | |||
| P2860 | cites work | Quantification of etravirine (TMC125) in plasma, dried blood spots and peripheral blood mononuclear cell lysate by liquid chromatography tandem mass spectrometry | Q33441519 |
| On-line desorption of dried blood spot: A novel approach for the direct LC/MS analysis of micro-whole blood samples | Q33442157 | ||
| Dried blood spot sampling in combination with LC-MS/MS for quantitative analysis of small molecules | Q33519108 | ||
| Influence of route of administration on drug availability | Q34226637 | ||
| Use of filter paper for the collection and analysis of human whole blood specimens | Q34243308 | ||
| What a drop can do: dried blood spots as a minimally invasive method for integrating biomarkers into population-based research | Q37071788 | ||
| Dried blood spot methods in therapeutic drug monitoring: methods, assays, and pitfalls | Q37435855 | ||
| Application of dried blood spots combined with HPLC-MS/MS for the quantification of acetaminophen in toxicokinetic studies. | Q44725242 | ||
| Application of dried blood spots combined with high-performance liquid chromatography coupled with electrospray ionisation tandem mass spectrometry for simultaneous quantification of vincristine and actinomycin-D. | Q46039984 | ||
| Study of dried blood spots technique for the determination of dextromethorphan and its metabolite dextrorphan in human whole blood by LC-MS/MS. | Q46112178 | ||
| Therapeutic drug monitoring of everolimus using the dried blood spot method in combination with liquid chromatography-mass spectrometry | Q46156222 | ||
| Dried blood spots as a sample collection technique for the determination of pharmacokinetics in clinical studies: considerations for the validation of a quantitative bioanalytical method. | Q46156878 | ||
| Effects of some hematological parameters on whole blood tacrolimus concentration measured by two immunoassay-based analytical methods | Q46483120 | ||
| Mechanistic approaches to volume of distribution predictions: understanding the processes. | Q51919468 | ||
| Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. | Q51975107 | ||
| Nonlinear relationship between plasma and red blood cell pharmacokinetics of chlorthalidone in man | Q67657469 | ||
| Monitoring of cyclosporine concentrations by using dry blood-spot samples | Q68207164 | ||
| Saturable binding of cyclosporin A to erythrocytes: estimation of binding parameters in renal transplant patients and implications for bioavailability assessment | Q70261857 | ||
| Plasma protein binding of tacrolimus in humans | Q72072986 | ||
| Physiologically based pharmacokinetic study on a cyclosporin derivative, SDZ IMM 125 | Q72335161 | ||
| Physiologically based pharmacokinetics of cyclosporine A: extension to tissue distribution kinetics in rats and scale-up to human | Q77532117 | ||
| Therapeutic drug monitoring of tacrolimus with the dried blood spot method | Q79447508 | ||
| Influence of hematocrit and localisation of punch in dried blood spots on levels of amino acids and acylcarnitines measured by tandem mass spectrometry | Q79782291 | ||
| Discovery stage pharmacokinetics using dried blood spots | Q80391679 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacokinetics | Q323936 |
| P304 | page(s) | 290-293 | |
| P577 | publication date | 2010-04-10 | |
| P1433 | published in | The AAPS Journal | Q10695361 |
| P1476 | title | Use of dried blood spots in drug development: pharmacokinetic considerations | |
| P478 | volume | 12 |
| Q39985425 | A clinical validation study for application of DBS in therapeutic drug monitoring of antidepressants |
| Q43943752 | A simple assay for determination of levetiracetam in rat dried blood spots by LC-MS/MS. |
| Q37954706 | Absolute quantitation of protein therapeutics in biological matrices by enzymatic digestion and LC-MS. |
| Q38560254 | Alternative Sampling Strategies for Cytochrome P450 Phenotyping. |
| Q38790456 | An Integrated Strategy for Implementation of Dried Blood Spots in Clinical Development Programs. |
| Q42066076 | Analysis of tacrolimus and creatinine from a single dried blood spot using liquid chromatography tandem mass spectrometry |
| Q47191113 | Application of DBS sampling in combination with LC-MS/MS for pharmacokinetic evaluation of a compound with species-specific blood-to-plasma partitioning |
| Q33810432 | Application of dried blood spot sampling combined with LC-MS/MS for genotyping and phenotyping of CYP450 enzymes in healthy volunteers |
| Q49116021 | Are capillary DBS applicable for therapeutic drug monitoring of common antipsychotics? A proof of concept |
| Q39039971 | Automated Microsampling Technologies and Enhancements in the 3Rs. |
| Q51788747 | Bioanalysis of emixustat (ACU-4429) in whole blood collected with volumetric absorptive microsampling by LC-MS/MS. |
| Q51756200 | Blood microsampling using capillaries for drug-exposure determination in early preclinical studies: a beneficial strategy to reduce blood sample volumes. |
| Q49053884 | CYP1A2 phenotyping in dried blood spots and microvolumes of whole blood and plasma |
| Q37359919 | Determination of efavirenz in human dried blood spots by reversed-phase high-performance liquid chromatography with UV detection |
| Q82483202 | Development and Validation of an HPLC–MS/MS Method for The Analysis of Dexamethasone from Pig Synovial Fluid Using Dried Matrix Spotting |
| Q35030893 | Development of an ultra fast online-solid phase extraction (SPE) liquid chromatography electrospray tandem mass spectrometry (LC-ESI-MS/MS) based approach for the determination of drugs in pharmacokinetic studies. |
| Q40988516 | Dried blood spot analysis for rat and dog studies: validation, hematocrit, toxicokinetics and incurred sample reanalysis |
| Q43656996 | Dried blood spot sampling: coupling bioanalytical feasibility, blood-plasma partitioning and transferability to in vivo preclinical studies |
| Q36620231 | Dried blood spots and sparse sampling: a practical approach to estimating pharmacokinetic parameters of caffeine in preterm infants. |
| Q37859735 | Dried blood spots, pharmacokinetic studies and better medicines for children. |
| Q38201371 | Dried blood spots: concepts, present status, and future perspectives in bioanalysis |
| Q38201783 | Emerging liquid chromatography-mass spectrometry technologies improving dried blood spot analysis |
| Q39791872 | Evaluation of blood microsampling techniques and sampling sites for the analysis of drugs by HPLC-MS. |
| Q54562543 | Evaluation of peripheral blood microsampling techniques in combination with liquid chromatography-high resolution mass spectrometry for the determination of drug pharmacokinetics in clinical studies. |
| Q82482333 | Exploring the Feasibility of Using the DBS Technique for Metabolite Radioprofiling |
| Q37872318 | GlaxoSmithKline's experience of incurred sample reanalysis for dried blood spot samples |
| Q38128343 | Hemato-critical issues in quantitative analysis of dried blood spots: challenges and solutions |
| Q41984975 | Impact of various factors on radioactivity distribution in different DBS papers |
| Q43192927 | Implementing dried blood spot sampling for clinical pharmacokinetic determinations: considerations from the IQ Consortium Microsampling Working Group |
| Q38810590 | Is there a role for microsampling in antibiotic pharmacokinetic studies? |
| Q83213156 | Oral flurbiprofen metabolic ratio assessment using a single-point dried blood spot |
| Q82483142 | Pharmacokinetic Considerations as to When to Use Dried Blood Spot Sampling |
| Q48831121 | Potassium-based algorithm allows correction for the hematocrit bias in quantitative analysis of caffeine and its major metabolite in dried blood spots |
| Q51275877 | Preclinical bridging studies: understanding dried blood spot and plasma exposure profiles. |
| Q47135581 | Quantitative analysis of biofluid spots by coated blade spray mass spectrometry, a new approach to rapid screening. |
| Q38153802 | Recent advances in the bioanalytical applications of dried matrix spotting for the analysis of drugs and their metabolites |
| Q38130332 | State-of-the-art dried blood spot analysis: an overview of recent advances and future trends. |
| Q40481558 | Structure-guided design of novel Trypanosoma brucei Methionyl-tRNA synthetase inhibitors. |
| Q37864339 | Surgical and pharmacological animal models used in drug metabolism and pharmacokinetics |
| Q43323352 | The Application of Dried Blood Spot Sampling in Global Clinical Trials |
| Q38253959 | The use of mass spectrometry to analyze dried blood spots |
| Q42607519 | Update of the EBF recommendation for the use of DBS in regulated bioanalysis integrating the conclusions from the EBF DBS-microsampling consortium |
| Q48221188 | Use of conventional bioanalytical devices to automate DBS extractions in liquid-handling dispensing tips |
| Q48860532 | Use of dried blood spots for the determination of serum concentrations of tamoxifen and endoxifen |
| Q30922388 | Using dried blood spot sampling to improve data quality and reduce animal use in mouse pharmacokinetic studies |
| Q49060953 | Why dried blood spots are an ideal tool for CYP1A2 phenotyping |
Search more.